Two cases demonstrate an association between Tropheryma whipplei and pulmonary marginal zone lymphoma

Autor: J. D. Haslbauer, C. Wiegand, B. Hamelin, V. S. Ivanova, T. Menter, S. Savic Prince, A. Tzankov, K. D. Mertz

Publikováno v: Infectious Agents and Cancer, Vol 19, Iss 1, Pp 1-10 (2024)

Abstract Background Marginal zone lymphomas of mucosa-associated lymphatic tissues (MZL of MALT) are a group of indolent B-cell neoplasms, which are thought to arise from chronic antigenic stimulation of B-cells either due to underlying chronic infec

Externí odkaz: https://doaj.org/article/051eb4ccd9e749ee955d5786970a11ff

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

EP16.01-018 SAKK 16/14 -Peripheral Immune Cell Populations Inresponse to Neoadjuvant Durvalumab in Patients with Stage IIIA(N2) NSCLC

Autor: D. Schmid, M. Trueb, P. Herzig, C. Gärtner-Pelham, I. Alborelli, K. Leonards, M. Manzo, P. Jermann, S. Savic Prince, E. Keller, E.I. Eboulet, S. Hayoz, G. Godar, M. Schneider, D. König, M. Pless, A. Zippelius, S.I. Rothschild

Publikováno v: Journal of Thoracic Oncology. 17:S562-S563

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82807264852708a83dabd1ba06998f17
https://doi.org/10.1016/j.jtho.2022.07.1018

Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study

Autor: M L Amrein, S Savic-Prince, Adrian F. Ochsenbein, Michael A. Amrein, Elias D. Bührer, Rolf Jaggi, Sacha I. Rothschild, Lukas Bubendorf, Qiyu Li, Carsten Riether, O. Gautschi

Publikováno v: Amrein, M. A.; Bührer, E. D.; Amrein, M. L.; Li, Q.; Rothschild, S.; Riether, C.; Jaggi, R.; Savic-Prince, S.; Bubendorf, L.; Gautschi, O.; Ochsenbein, A. (2021). Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre-and post-treatment biopsies in the multi-center SAKK19/09 study. Cancer immunology, immunotherapy : CII, 70(2), pp. 405-415. Springer 10.1007/s00262-020-02688-4
Cancer Immunology, Immunotherapy

Background Over the past few years, immune checkpoint inhibitors have changed the therapeutic landscape of non-small-cell lung cancer (NSCLC). Response to immune checkpoint inhibitors correlates with a pre-existing anti-tumoral immune response. Check

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c2a4c07e703a7e94e7638a8c438fa03
https://doi.org/10.1007/s00262-020-02688-4

MA09.02 SAKK 16/14 - T-Cell Receptor Repertoire Metrics Predict Response to Neoadjuvant Durvalumab in Patients With Stage IIIA(N2) NSCLC

Autor: Sacha I. Rothschild, Katharina Leonards, Philip Jermann, D. Schmid, Ilaria Alborelli, Petra Herzig, E. Keller, M. Manzo, Marta Trüb, Gilles Godar, Alfred Zippelius, E.I. Eboulet, Miklos Pless, S. Savic Prince

Publikováno v: Journal of Thoracic Oncology. 16:S911

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed4339539bbd3b297084f5d7b900713f
https://doi.org/10.1016/j.jtho.2021.08.153